{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:56:17Z","timestamp":1792792577080,"version":"4.5.0"},"reference-count":90,"publisher":"Informa UK Limited","issue":"12","funder":[{"name":"Biomedical Advanced Research and Development Authority, Assistant Secretary of Health and Human Services","award":["HHSO-100-2007-00037C."],"award-info":[{"award-number":["HHSO-100-2007-00037C."]}],"id":[{"id":"https:\/\/ror.org\/029y69023","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Vaccines"],"published-print":{"date-parts":[[2016,12,1]]},"DOI":"10.1080\/14760584.2016.1254556","type":"journal-article","created":{"date-parts":[[2016,10,28]],"date-time":"2016-10-28T12:34:52Z","timestamp":1477658092000},"page":"1467-1479","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":25,"title":["Licensure strategy for pre- and post-exposure prophylaxis of biothrax vaccine: the first vaccine licensed using the FDA animal rule"],"prefix":"10.1080","volume":"15","author":[{"given":"Janice","family":"Longstreth","sequence":"first","affiliation":[{"name":"Biodefense Division, Emergent BioSolutions Inc., Gaithersburg, MD, US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario H.","family":"Skiadopoulos","sequence":"additional","affiliation":[{"name":"Biodefense Division, Emergent BioSolutions Inc., Gaithersburg, MD, US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Hopkins","sequence":"additional","affiliation":[{"name":"Biodefense Division, Emergent BioSolutions Inc., Gaithersburg, MD, US"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2016,11,18]]},"reference":[{"key":"CIT0001","unstructured":"Anthrax in Humans and Animals 2008. Available from: http:\/\/apps.who.int\/iris\/bitstream\/10665\/97503\/1\/9789241547536_eng.pdf."},{"key":"CIT0002","first-page":"887","volume-title":"Vaccines","author":"Brachman PS","year":"2004","edition":"3"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1126\/science.7973702"},{"key":"CIT0004","unstructured":"Centers for Disease Control and Prevention. Update: Investigation of bioterrorism-related anthrax and interim guidelines for clinical evaluation of persons with possible anthrax. MMWR Morbidity and mortality weekly report. 2001;50:941\u2013948. Epub 2001 Nov 16."},{"key":"CIT0005","first-page":"877","volume-title":"MMWR Morbidity and mortality weekly report","volume":"50","author":"Centers for Disease Control and Prevention","year":"2001"},{"key":"CIT0006","unstructured":"Centers for Disease Control and Prevention. Update: Investigation of anthrax associated with intentional exposure and interim public health guidelines, October 2001. MMWR Morbidity and mortality weekly report. 2001;50:889\u2013893. Epub 2001 Nov 01."},{"key":"CIT0007","unstructured":"Centers for Disease Control and Prevention. Update: Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR Morbidity and mortality weekly report. 2001;50:909\u2013919. Epub 2001 Nov 09."},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1080\/1359084021000036765"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1017\/S0022172400044272"},{"key":"CIT0010","volume-title":"The anthrax vaccine: is it safe? does it work?","author":"IOM Institute of Medicine, U.S. National Academy of Sciences","year":"2002"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.52.4.632"},{"key":"CIT0012","unstructured":"Zoon KC Vaccine licensing: statement before the house committee on government reform12 october 1999 [cited 2016 Feb 28]. Available from: http:\/\/www.fda.gov\/NewsEvents\/Testimony\/ucm115037.htm."},{"key":"CIT0013","unstructured":"Zoon KC. Safety and efficacy of the anthrax vaccine: statement before the subcommittee on national security, veterans affairs, and international relations, house committee on government reform29 April 1999 [cited 2016 Feb 06]. Available from: http:\/\/www.fda.gov\/newsevents\/testimony\/ucm115072.htm."},{"key":"CIT0014","first-page":"1","volume":"49","author":"Centers for Disease Control and Prevention","year":"2000","journal-title":"MMWR Recomm Rep"},{"key":"CIT0015","unstructured":"US FDA US Food and Drug Administration. Accelerated approval. Silver spring MD2015 [cited 2016 Oct 10]. Available from: http:\/\/www.fda.gov\/ForPatients\/Approvals\/Fast\/ucm405447.htm"},{"key":"CIT0016","unstructured":"CBER _CDER. Center for Drug Evaluation and Research & Center for Biologics Evaluation and Research USFaDA. Guidance for Industry: Product Development Under the Animal Rule2015. Available from: http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm399217.pdf."},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.05.054"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.03.071"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2016.1162104"},{"key":"CIT0020","volume-title":"Guidelines for the surveillance and control of anthrax in humans and animals","author":"Turnbull PCB","year":"1998"},{"key":"CIT0021","unstructured":"Centers for Disease Control and Prevention. Inhalation anthrax associated with dried animal hides\u2013Pennsylvania and New York City, 2006. MMWR Morbidity and mortality weekly report. 2006;55:280\u2013282. Epub 2006 Mar 18."},{"key":"CIT0022","unstructured":"Centers for Disease Control and Prevention. Gastrointestinal anthrax after an animal-hide drumming event - New Hampshire and Massachusetts, 2009. MMWR Morbidity and mortality weekly report. 2010;59:872\u2013877. Epub 2010 Jul24."},{"key":"CIT0023","first-page":"1","volume":"61","author":"Adams DA","year":"2014","journal-title":"MMWR Morbidity and mortality weekly report"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.3201\/eid2002.130021"},{"key":"CIT0025","volume-title":"Medical microbiology [Internet]","author":"Turnbull PCB","year":"1998","edition":"4"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-micro-091014-104523"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2012.00076"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.68.4.617-629.2004"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2003.07.004"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.12.028"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(01)00234-1"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2005.01.028"},{"key":"CIT0033","unstructured":"Wright JG, Quinn CP, Shadomy S, et al. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recommendations and reports: Morbidity and mortality weekly report Recommendations and reports \/Centers for Disease Control. 2010;59:1\u201330. Epub 2010 Jul 24."},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.3201\/eid0810.020353"},{"key":"CIT0035","unstructured":"CDC. Centers for Disease Control and Prevention. Department of Health and Human Services. Injection Anthrax. Atlanta: GA2014. updated. [2014 Jul 21; cited 2016 Feb 20]. Available from: http:\/\/www.cdc.gov\/anthrax\/basics\/types\/injection.html"},{"issue":"13","key":"CIT0036","doi-asserted-by":"crossref","first-page":"20437","DOI":"10.2807\/ese.18.13.20437-en","volume":"18","author":"Grunow R","year":"2013","journal-title":"Euro Surveill"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03550050074036"},{"key":"CIT0038","first-page":"15","volume":"14","author":"Davis J","year":"2000","journal-title":"Aerospace Power Journal"},{"key":"CIT0039","volume-title":"Terrorism: threat, reality, response","author":"Kupperman RH","year":"1979"},{"key":"CIT0040","unstructured":"Carus WS Bioterrorism and biocrimes: the illicit use of biological agents since 1900August 1998[cited 2016 Apr 21]. Available from: http:\/\/www.dtic.mil\/dtic\/tr\/fulltext\/u2\/a402108.pdf."},{"key":"CIT0041","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268800068497"},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1085"},{"key":"CIT0043","unstructured":"Davis KLA 2011 risk\/benefit analysis of the anthrax vaccine immunization program [Published]: U.S. Army Command and General Staff College. 2011 [cited 2011 Jun 10]. Available from: https:\/\/www.hsdl.org\/?view&did=683115."},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.3201\/eid0810.020349"},{"key":"CIT0045","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2009.06.004"},{"key":"CIT0046","first-page":"307","volume":"13","author":"Sterne M","year":"1939","journal-title":"Onderstepoort J Vet Sci Anim Ind"},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.1038\/emi.2014.82"},{"key":"CIT0048","doi-asserted-by":"publisher","DOI":"10.3390\/toxins8030056"},{"key":"CIT0049","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1128\/JB.68.4.474-482.1954","volume":"68","author":"Puziss M","year":"1954","journal-title":"J Bacteriol"},{"key":"CIT0050","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1128\/IAI.2.6.772-777.1970","volume":"2","author":"Wright GG","year":"1970","journal-title":"Infect Immun"},{"key":"CIT0051","doi-asserted-by":"crossref","first-page":"263","DOI":"10.4049\/jimmunol.72.4.263","volume":"72","author":"Wright GG","year":"1954","journal-title":"J Immunol"},{"key":"CIT0052","doi-asserted-by":"crossref","first-page":"387","DOI":"10.4049\/jimmunol.73.6.387","volume":"73","author":"Wright GG","year":"1954","journal-title":"J Immunol"},{"key":"CIT0053","doi-asserted-by":"publisher","DOI":"10.1084\/jem.93.6.523"},{"key":"CIT0054","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1128\/JB.83.3.515-522.1962","volume":"83","author":"Wright GG","year":"1962","journal-title":"J Bacteriol"},{"key":"CIT0055","doi-asserted-by":"publisher","DOI":"10.1084\/jem.93.2.99"},{"key":"CIT0056","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1128\/AEM.11.4.330-334.1963","volume":"11","author":"Puziss M","year":"1963","journal-title":"Appl Microbiol"},{"key":"CIT0057","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4049\/jimmunol.75.2.129","volume":"75","author":"Auerbach S","year":"1955","journal-title":"J Immunol"},{"key":"CIT0058","unstructured":"Emergent_BioSolutions_Inc. BioThrax prescribing information. November 2015. Available from: http:\/\/www.biothrax.com\/prescribinginformation_biothrax_us.pdf."},{"key":"CIT0059","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(01)00462-5"},{"key":"CIT0060","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.10.039"},{"key":"CIT0061","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.01.054"},{"key":"CIT0062","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(02)00058-0"},{"key":"CIT0063","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(01)00387-5"},{"key":"CIT0064","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(02)00172-X"},{"key":"CIT0065","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.06.026"},{"key":"CIT0066","doi-asserted-by":"publisher","DOI":"10.1001\/jama.300.13.1532"},{"key":"CIT0067","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00469-14"},{"key":"CIT0068","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00324-12"},{"key":"CIT0069","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.05.091"},{"key":"CIT0070","unstructured":"Merck_Sharp_&_Dohme_Corp. GARDASIL\u00ae9 (Human Papillomavirus 9-valent Vaccine, Recombinant) Prescribing Information 2014: first US approval Oct 2016. Available from: https:\/\/www.merck.com\/product\/usa\/pi_circulars\/g\/gardasil_9\/gardasil_9_pi.pdf."},{"key":"CIT0071","unstructured":"GSK, GlaxoSmithKline_Biologicals. ENERIX\u00ae-B [hepatitis B vaccine (recombinant)] prescribing information1989: initial US approval May 2016 2016. Available from: https:\/\/www.gsksource.com\/pharma\/content\/dam\/GlaxoSmithKline\/US\/en\/Prescribing_Information\/Engerix-B\/pdf\/ENGERIX-B.PDF."},{"key":"CIT0072","unstructured":"GSK, GlaxoSmithKline_Biologicals. TWINRIX [hepatitis A & hepatitis B (recombinant) vaccine] prescribing information2001: first US approval May 2016 2016. Available from: https:\/\/www.gsksource.com\/pharma\/content\/dam\/GlaxoSmithKline\/US\/en\/Prescribing_Information\/Twinrix\/pdf\/TWINRIX.PDF."},{"key":"CIT0073","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00696-15"},{"key":"CIT0074","unstructured":"Centers for Disease Control and Prevention. Evaluation of Bacillus anthracis contamination inside the Brentwood Mail Processing and Distribution Center \u2014 District of Columbia, October 2001. MMWR Morbidity and mortality weekly report. 2001;50:1129\u20131133. Epub 2001 Dec 21."},{"key":"CIT0075","doi-asserted-by":"publisher","DOI":"10.3201\/eid0810.020223"},{"key":"CIT0076","doi-asserted-by":"publisher","DOI":"10.1086\/377738"},{"key":"CIT0077","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00099-13"},{"key":"CIT0078","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0602748103"},{"key":"CIT0079","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00458-13"},{"key":"CIT0080","volume-title":"Vaccines and related biological products advisory committee meeting presentations Silver Spring, MD, 2010 Nov 16\u201317","author":"CBER. Center for Biologics Evaluation and Research US Food and Drug Administration","year":"2015"},{"key":"CIT0081","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00003-08"},{"key":"CIT0082","first-page":"982","volume":"122","author":"Zaucha GM","year":"1998","journal-title":"Arch Pathol Lab Med"},{"key":"CIT0083","doi-asserted-by":"publisher","DOI":"10.1097\/01.LAB.0000080599.43791.01"},{"key":"CIT0084","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.01.073"},{"key":"CIT0085","volume-title":"A study of the effects of co-administering ciprofloxacin and biothrax on the pharmacokinetics of ciprofloxacin in healthy adults Bethesda MD","author":"Emergent EBI","year":"2014"},{"key":"CIT0086","volume-title":"U.S. government issues solicitation notices providing path to achieve a stockpile to protect 25 million people through procurement of up to 56.4 million doses of anthrax vaccines","author":"Emergent","year":"2016"},{"key":"CIT0087","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.08.076"},{"key":"CIT0088","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.04.048"},{"key":"CIT0089","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.03.006"},{"key":"CIT0090","unstructured":"Homeland Preparedness News. FDA approves sBLA for biothrax manufacture at emergent biosolutions\u2019 building 55.cited 2016 Aug 16. Available from: https:\/\/homelandprepnews.com\/biological-threats\/19502-fda-approves-sbla-biothrax-manufacture-emergent-biosolutions-building-55\/"}],"container-title":["Expert Review of Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14760584.2016.1254556","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T03:25:31Z","timestamp":1718853931000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14760584.2016.1254556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,18]]},"references-count":90,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12,1]]}},"alternative-id":["10.1080\/14760584.2016.1254556"],"URL":"https:\/\/doi.org\/10.1080\/14760584.2016.1254556","relation":{},"ISSN":["1476-0584","1744-8395"],"issn-type":[{"value":"1476-0584","type":"print"},{"value":"1744-8395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,18]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2016-09-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-10-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-11-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}